Nanjing-based biotech firm Lansion Biotechnology (Lansionbio) has raised nearly RMB100 million (US$14 million) in a series C round of financing led by Matrix Partners China with participation from Bondshine Capital.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?